Treatment of endotoxin-associated disorders with cationic peptid

Details Treatment of endotoxin-associated disorders with cationic peptid Treatment of endotoxin-associated disorders with cationic peptid

1995-03-13

1998-08-04

Patterson, Jr., Charles L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

435 697, A61K 3816

Patent

active

057893772

ABSTRACT:
A method for the microbial production of a cationic peptide having anti-microbial activity is provided, wherein the cationic peptide is first produced as a fusion protein having an anionic portion for suppressing the antimicrobial activity of the cationic portion. A novel cationic peptide having anti-microbial activity and LPS-binding activity is also provided. Such peptides are useful for suppressing the growth of bacteria and for the treatment of endotoxemia-associated disorders.

REFERENCES:
patent: 5344765 (1994-09-01), Lai et al.
patent: 5357044 (1994-10-01), Lai et al.
patent: 5484885 (1996-01-01), Pereira et al.
Kohn, F. R, et. al. (1993) J. Infect. Dis. 168(5), 1307-1310.
Larrick, J. W., et. al. (1994) J. Immunol. 152(1), 231-240.
Coyne, C. P., et. al. (1993) Am. J. Vet. Res. 54(2), 305-314.
Sawyer, J. G., et.al. (1988) Infect. Immun 56(3), 693-698.
Wade, D., et, al. (1992) Int. J. Pept. Protein Res. 40(5), 429-436.

Affiliated with

Also associated with

Rating

Treatment of endotoxin-associated disorders with cationic peptid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of endotoxin-associated disorders with cationic peptid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of endotoxin-associated disorders with cationic peptid will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1177195